Boundless Bio Inc. Common Stock (BOLD)
Stock · NASDAQ · Health Care
$2.33as of 10/16/2026
Price chart
Active signals
BOLD Signal Track Record
How signals performed across all stocks →What BOLD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume SpikeActive now | 18 | +5.3% | 61% | October 8, 2026 |
| Bollinger Band Breakout | 10 | -2.7% | 40% | July 24, 2026 |
| Bollinger Band Breakdown | 5 | +6.5% | 60% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 5 | -2.4% | 40% | April 6, 2026 |
| Any 20-session window (baseline) | -0.9% | 45% |
Computed by MarketWall from daily closing prices since January 14, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BOLD
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 28
- Website
- boundlessbio.com/
Fundamentals
- 1-day range
- $2.29$2.4
- Market cap
- $63.80M
- P/E (trailing)
- —
- P/E (forward)
- -2.39
- EPS (trailing)
- $-2.86
- Dividend yield
- —
- Beta
- 0.45
- Avg. volume
- 177.5K
Forecasts
1 analyst ratings
Boundless Bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BOLDBoundless Bio Inc. Common Stock$2.34▼ 0.43%Market cap $63.80MP/E —$0.9612$3.16
- ANVSAnnovis Bio Inc. Common Stock$0.99▼ 5.71%Market cap $64.44MP/E —$1.01$5.5
- PMVPPMV Pharmaceuticals Inc. Common Stock$1.21▼ 6.20%Market cap $62.93MP/E —$1.02$1.91
- PLRXPliant Therapeutics Inc. Common Stock$0.9▼ 7.41%Market cap $65.02MP/E —$0.8838$1.95
- MNOVMedicinova Inc Common Stock$1.42▼ 2.07%Market cap $66.94MP/E —$1.17$3.9
- RNTXRein Therapeutics Inc. Common Stock$0.59▼ 6.05%Market cap $67.45MP/E —$0.5401$2.18
- HYFTMindWalk Holdings Corp. Common Stock$1.31▼ 6.43%Market cap $59.79MP/E —$0.99$2.99
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BOLD Boundless Bio Inc. Common Stock | $63.80M | — | $2.34 | ▼ 0.43% | $0.9612$3.16 |
| ANVS Annovis Bio Inc. Common Stock | $64.44M | — | $0.99 | ▼ 5.71% | $1.01$5.5 |
| PMVP PMV Pharmaceuticals Inc. Common Stock | $62.93M | — | $1.21 | ▼ 6.20% | $1.02$1.91 |
| PLRX Pliant Therapeutics Inc. Common Stock | $65.02M | — | $0.9 | ▼ 7.41% | $0.8838$1.95 |
| MNOV Medicinova Inc Common Stock | $66.94M | — | $1.42 | ▼ 2.07% | $1.17$3.9 |
| RNTX Rein Therapeutics Inc. Common Stock | $67.45M | — | $0.59 | ▼ 6.05% | $0.5401$2.18 |
| HYFT MindWalk Holdings Corp. Common Stock | $59.79M | — | $1.31 | ▼ 6.43% | $0.99$2.99 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- TANG KEVIN · August 26, 2026 · Sale18.3K @ $2.97
- TANG KEVIN · July 21, 2026 · Buy3.0K @ $2.44
- TANG KEVIN · July 20, 2026 · Buy1.6K @ $2.44
- TANG KEVIN · July 17, 2026 · Buy265 @ $2.44
- TANG KEVIN · July 16, 2026 · Buy18.5K @ $2.44
- TANG KEVIN · July 15, 2026 · Buy1.6K @ $2.44
- TANG KEVIN · July 14, 2026 · Buy43.9K @ $2.43
- TANG KEVIN · July 13, 2026 · Buy48.2K @ $2.42
- TANG KEVIN · July 10, 2026 · Buy43.4K @ $2.43
- TANG KEVIN · July 9, 2026 · Buy7 @ $2.48
- TANG KEVIN · July 8, 2026 · Buy14.3K @ $2.46
- TANG KEVIN · July 7, 2026 · Buy15.8K @ $2.48
- TANG KEVIN · July 6, 2026 · Buy27.1K @ $2.49
- TANG KEVIN · July 2, 2026 · Buy9.8K @ $2.49
- ARCH Venture Fund IX, L.P. · July 1, 2026 · Option Exercise16.0K @ $1.03
Institutional Ownership
March 31, 2026
- Total shares held
- 8.42M
- Total value held
- $9.14M
- Institutional holders
- 33
- Unknown2.70M
- Unknown1.34M
- Unknown678.6K
- Unknown597.7K
- Unknown597.2K
- Unknown556.2K
- Unknown399.0K
- Unknown300.0K
- Unknown200.0K
- Unknown187.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
BOLD trades near support amid sector news
Recent headlines focus on Beam Therapeutics and Callio Therapeutics rather than direct developments for Boundless Bio. The stock is currently trading near its identified support level, with technical indicators showing a breakdown signal. Analysts maintain a single price target of $4.00, which sits above the current trading range.
BOLD trades near support amid sector news. Recent headlines focus on Beam Therapeutics and Callio Therapeutics rather than direct developments for Boundless Bio. The stock is currently trading near its identified support level, with technical indicators showing a breakdown signal. Analysts maintain a single price target of $4.00, which sits above the current trading range.